PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

2 targeted therapies act against Ewing's sarcoma tumors

Researchers control drug side effects for treatment gains in Phase I trial

2012-04-02
(Press-News.org) CHICAGO - A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.

Five of 17 Ewing's sarcoma patients responded to the combination, with two achieving complete responses, one for 27 weeks. The researchers noted that the ability to manage patients' treatment-related side effects is vital to maintaining the therapy and slowing disease progression.

The study was published simultaneously in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Ewing's sarcoma primarily affects the bones and occurs most often in teenagers and young adults and relapse is common, said lead researcher Aung Naing, M.D., assistant professor in MD Anderson's Department of Investigational Cancer Therapeutics.

Researchers used a combination of cixutumumab, a human IgG1 monoclonal antibody that targets insulin growth factor receptor 1 (IGF-1R), and temsirolimus, an agent that inhibits mTOR, or "mammalian target of rapamycin". The two drugs address molecular pathways that cause cell proliferation and survival, abnormal blood vessel growth and resistance to chemotherapy and radiotherapy.

Encouraging Responses in Treatment-Resistant Patients

Twenty patients were enrolled in the phase I clinical trial - 17 with Ewing's sarcoma and three with desmoplastic small-round cell tumors (DSRCT). The patients were treated with cixutumumab (6 mg/kg i.v. each week) and temsirolimus (25 to 37.5 mg i.v. each week) in 4-week cycles. Median follow-up was 8.9 months.

"Seven of the 20 patients responded and have had stable disease for more than five months," Naing said. "Five of these responders have Ewing's sarcoma and have had tumor reductions of more than 20 percent. Treatment responses have lasted 8 to 27 months."

Naing added that these patients had undergone a median of six previous treatments. "They had been heavily, heavily pre-treated and are quite resistant to most other treatments," Naing said. "So we are encouraged that 5 of 17 patients with Ewing's sarcoma-about 29 percent-responded to the treatment, with two achieving complete responses."

The investigators noted that when the two drugs had been used as single agents, treatment results were mixed. They theorized that combining the drugs would help stave off onset of drug resistance, a common occurrence and major obstacle in cancer treatment.

"This trial provides preliminary data indicating that combining two targeted agents can result in tumor regression and even complete remission in heavily pretreated patients with metastatic Ewing's sarcoma, including those whose tumors had progressed on an IGFR inhibitor alone," said study senior author Razelle Kurzrock, M.D., professor and chair of the Department of Investigational Cancer Therapeutics. "By giving combinations of drugs in a scientifically rational way, we may be able to overcome resistance to single agents and provide benefit to patients with advanced Ewing's sarcoma."

Managing Treatment Toxicities

The most common treatment-related side effects were reduced platelet levels (85 percent), mucositis (80 percent), elevated cholesterol (75 percent), high triglycerides (70 percent), and elevated blood sugar (65 percent).

Naing noted that it is not unusual to see these side effects, which were mostly grade I or grade II in severity. He added that one of the patients developed diabetes, which was eventually managed with insulin and the diabetes medication metformin.

Non-hematologic side effects of the treatment included mucositis, fatigue, rash or itching, elevated AST/ALT, elevated creatinine, diarrhea, anorexia/weight loss, and nausea and vomiting. The ability to manage these and other treatment side effects is critically important, Naing said.

"Our four best responders had grade III mucositis or grade III myelosuppression, such as thrombocytopenia or neutropenia. Typically, a patient who develops these types of grade III toxicities would be removed from the study," Naing said. "But we were able to continue with the treatment after we received approval from the sponsor and notification from our institutional review board. Our patients received the benefits of continued treatment because we were able to manage their toxicities."

Supportive Care Aids Treatment

According to the researchers, the study results suggest patients should receive supportive care that will help them achieve and maintain dose levels high enough to sustain their response.

"If we can manage the toxicity, patients should not be taken off treatment," Naing said. "This is a really important message."

Co-authors Robert Benjamin, M.D., professor and chair of MD Anderson's Department of Sarcoma Medical Oncology, and Joseph Ludwig, M.D., assistant professor in the department, plan further studies in larger numbers of patients with Ewing's sarcoma and DSRCT, as well as additional investigation into underlying resistance mechanisms in individual patients.

INFORMATION:

This research was supported by grants from the National Cancer Institute.

Co-authors with Naing, Kurzrock, Benjamin and Ludwig are Siqing Fu, M.D., Ph.D., and David Hong, M.D., of the Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Pete Anderson, M.D., Ph.D., of MD Anderson's Department of Pediatrics; Patricia LoRusso, D.O., of the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit, Michigan; and Helen X. Chen, M.D., and Lawrence A. Doyle, M.D., of the Cancer Therapy Evaluation Program at the NIH/National Cancer Institute in Rockville, Maryland.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 41 comprehensive cancer centers designated by the National Cancer Institute. For eight of the past 10 years, including 2011, MD Anderson has ranked No. 1 in cancer care in the "Best Hospitals" survey published annually in U.S. News & World Report.

END



ELSE PRESS RELEASES FROM THIS DATE:

Commonly used diabetes drug may help to prevent primary liver cancer

2012-04-02
Baltimore, MD – March 31, 2012. Metformin, a drug widely used to treat Type II diabetes, may help to prevent primary liver cancer, researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center report in the April 2012 issue of Cancer Prevention Research. Primary liver cancer, or hepatocellular carcinoma, is an often-deadly form of cancer that is on the rise worldwide and is the fastest-growing cause of cancer-related deaths among American men. Patients with Type II diabetes have a two- to three-fold increased relative risk of developing primary ...

Transforming scar tissue into beating hearts: The next instalment

2012-04-02
London -- The latest research developments to reprogram scar tissue resulting from myocardial infarction (MI) into viable heart muscle cells, were presented at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, held 30 March to 1 April at the South Kensington Campus of Imperial College in London. In a keynote lecture Dr Deepak Srivastava outlined his approach that has been described as a "game changer" with the potential to revolutionise treatment of MI. For the first time at the FCVB meeting, Srivastava presented the results of his latest studies using ...

Second mutation in BRAF-mutated melanoma doesn't contribute to resistance

2012-04-02
A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true. The study by researchers at UCLA's Jonsson Comprehensive Cancer Center found that patients with the mutations in both the MEK1 and BRAF genes respond as well to the inhibitors as patients with the BRAF mutation alone. Another surprising finding is that the MEK1 and BRAF mutations exist together in these patients, despite the fact that they drive ...

Study finds protective gene in fat cells

2012-04-02
BOSTON -- In a finding that may challenge popular notions of body fat and health, researchers at Beth Israel Deaconess Medical Center (BIDMC) have shown how fat cells can protect the body against diabetes. The results may lead to a new therapeutic strategy for preventing and treating type 2 diabetes and obesity-related metabolic diseases, the authors say. In the last decade, several research groups have shown that fat cells in people play a major role in controlling healthy blood sugar and insulin levels throughout the body. To do this crucial job, fat cells need a small ...

MDC-researchers elucidate molecular mechanism contributing to cardiomyopathy

2012-04-02
Cardiomyopathy comprises a deterioration of the heart muscle that affects the organ's ability to efficiently pump blood through the body. Previously researchers have tied forms of the disease to the alternative splicing of titin, a giant protein that determines the structure and biomechanical properties of the heart, but the molecular mechanism remained unknown. Professor Michael Gotthardt and Professor Norbert Hübner of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Germany, and colleagues have found that the RNA binding motif protein 20 (RBM20), a gene ...

Heart failure's effects in cells can be reversed with a rest

2012-04-02
Structural changes in heart muscle cells after heart failure can be reversed by allowing the heart to rest, according to research at Imperial College London. Findings from a study in rats published today in the European Journal of Heart Failure show that the condition's effects on heart muscle cells are not permanent, as has generally been thought. The discovery could open the door to new treatment strategies. Heart failure means that the heart muscle is too weak or stiff to pump blood as effectively as it needs to, and it is commonly the result of a heart attack. Around ...

The role of physics in the sinking of the Titanic

2012-04-02
A century on from the sinking of the Titanic, science writer Richard Corfield takes a look at the cascade of events that led to the demise of the 'unsinkable' ship, taking into account the maths and physics that played a significant part. At 11.40 p.m. on Sunday 14 April 1912 the Titanic, bound from Southampton to New York, struck an iceberg just off the coast of Newfoundland and became fully submerged within three hours, before dropping four kilometres to the bottom of the Atlantic. There have been many stories recounting why the ship struck the iceberg and why two-thirds ...

Mechanism found connecting metastatic breast cancer and arthritis

2012-04-02
New research shows it may be no accident when doctors observe how patients suffering from both breast cancer and arthritis seem to have more aggressive cancer. However, the new-found interaction between the two diseases may also suggest a possible treatment. A potential relationship between metastatic breast cancer and autoimmune arthritis, as suggested by past epidemiological studies, has led researchers from the University of North Carolina at Charlotte to perform a series of mouse model experiments that appear to confirm the connection. "Epidemiological studies ...

Protein Aurora-A is found to be associated with survival in head and neck cancer

2012-04-02
CHICAGO, IL (April 1, 2012)––Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1. The researchers found that patients whose tumors had higher levels of the protein known as Aurora-A had a shorter survival following surgery to remove their tumors than patients whose tumors had normal levels of the protein. "This ...

The protein survivin could be a useful biomarker for pancreatic cancer

2012-04-02
CHICAGO, IL (April 1, 2012)––Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute. New research from scientists at Fox Chase Cancer Center in Philadelphia, which will be presented at the AACR Annual ...

LAST 30 PRESS RELEASES:

Exercise as an anti-ageing intervention to avoid detrimental impact of mental fatigue

UMass Amherst Nursing Professor Emerita honored as ‘Living Legend’

New guidelines aim to improve cystic fibrosis screening

Picky eaters by day, buffet by night: Butterfly, moth diets sync to plant aromas

Pennington Biomedical’s Dr. Leanne Redman honored with the E. V. McCollum Award from the American Society for Nutrition

CCNY physicists uncover electronic interactions mediated via spin waves

Researchers’ 3D-printing formula may transform future of foam

Nurture more important than nature for robotic hand

Drug-delivering aptamers target leukemia stem cells for one-two knockout punch

New study finds that over 95% of sponsored influencer posts on Twitter were not disclosed

New sea grant report helps great lakes fish farmers navigate aquaculture regulations

Strain “trick” improves perovskite solar cells’ efficiency

How GPS helps older drivers stay on the roads

Estrogen and progesterone stimulate the body to make opioids

Dancing with the cells – how acoustically levitating a diamond led to a breakthrough in biotech automation

Machine learning helps construct an evolutionary timeline of bacteria

Cellular regulator of mRNA vaccine revealed... offering new therapeutic options

Animal behavioral diversity at risk in the face of declining biodiversity

Finding their way: GPS ignites independence in older adult drivers

Antibiotic resistance among key bacterial species plateaus over time

‘Some insects are declining but what’s happening to the other 99%?’

Powerful new software platform could reshape biomedical research by making data analysis more accessible

Revealing capillaries and cells in living organs with ultrasound

American College of Physicians awards $260,000 in grants to address equity challenges in obesity care

Researchers from MARE ULisboa discover that the European catfish, an invasive species in Portugal, has a prolonged breeding season, enhancing its invasive potential

Rakesh K. Jain, PhD, FAACR, honored with the 2025 AACR Award for Lifetime Achievement in Cancer Research

Solar cells made of moon dust could power future space exploration

Deporting immigrants may further shrink the health care workforce

Border region emergency medical services in migrant emergency care

Resident physician intentions regarding unionization

[Press-News.org] 2 targeted therapies act against Ewing's sarcoma tumors
Researchers control drug side effects for treatment gains in Phase I trial